hGRB14(2)
Nomenclature
C57BL/6JSmo-Grb14tm1(hGRB14)Smoc
Cat. NO.
NM-HU-251628
Strain State
Repository Live
Gene Summary
Gene Symbol
Grb14
Model Description
Validation Data

Fig.1 Detection of GRB14 expression in heart and liver by RT-PCR. Mouse Grb14 mRNA (225 bp) was detectable both in wild-type C57BL/6 mice and heterozygous hGRB14(2) knock-in mice. Human GRB14 mRNA (442 bp/872 bp/869 bp/396 bp/346 bp) was detectable only in heterozygous hGRB14(2) knock-in mice but not in wild-type mice. Heart and liver RNA was extracted from 8-week-old male wild-type C57BL/6 (WT)(n=2) and heterozygous hGRB14(2) knock-in mice (HE) (n=2), then cDNA libraries were synthesized by reverse transcription, followed by PCR with mRNA primers.
Abbr. M, marker; HE, heterozygous; WT, wild type.

Fig.2 Detection of GRB14 expression in hGRB14(2) mice by WB. GRB14 was detectable in the liver from both WT C57BL/6 and HE hGRB14(2) mice, as the antibody was cross-reactived between human and mouse GRB14. The liver lysates were collected from 8-week-old male wild-type C57BL/6 mice and 8-week-old male heterozygous hGRB14(2) mice, and then analyzed by western blot with anti-GRB14 antibody.
Abbr. HE, heterozygous; WT, wild type; PC, positive control, PC1, HepG2 cells, PC2, HT-1080 cells; M, marker.

Fig.3 Detection of GRB14 expression in hGRB14(2) mice by WB. GRB14 was detectable in heart and small intestine tissues from both WT C57BL/6 and HE hGRB14(2) mice, as the antibody was cross-reactived between human and mouse GRB14. The heart and small intestine lysates were collected from 8-week-old male wild-type C57BL/6 mice and 8-week-old male heterozygous hGRB14(2) mice, and then analyzed by western blot with anti-GRB14 antibody.
Abbr. HE, heterozygous; WT, wild type; PC, positive control, PC1, HepG2 cells, PC2, HT-1080 cells; M, marker.
You may also like
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreWorkshop:Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more